RxDoctor Payments Data

Jacob Brazee, MD

Internal Medicine · Myrtle Beach, SCNPI 1043630387

Payments from drug & device makers

$2,959in general payments, 2019–2025

Across 170 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$827
  • AbbVie$425
  • AstraZeneca$275
  • GSK$192
  • Amgen$125
  • Lilly USA, LLC$121
  • plus $994 from 24 others

What the payments were for

  • Food & beverage$2,91799%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,959 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$221,125
Medicare patients
564
Services billed
3,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$178,707
EliquisApixaban83$115,941
FarxigaDapagliflozin Propanediol56$61,688
JardianceEmpagliflozin44$42,965
XareltoRivaroxaban32$41,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,902
JanuviaSitagliptin Phosphate22$23,447
Tresiba Flextouch U-100Insulin Degludec21$11,949
Xigduo XrDapaglifloz Propaned/Metformin13$10,159
Atorvastatin Calcium838$9,246
Tiotropium Bromide12$7,959
Valsartan176$6,214
Levothyroxine Sodium495$4,872
Gabapentin229$4,269
Omeprazole281$4,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$827$178,707122 claims
PfizerEliquis$100$115,94183 claims
AstraZenecaFarxiga, Symbicort$275$65,77969 claims
Boehringer IngelheimJardiance$20$42,96544 claims
Johnson & JohnsonXarelto$28$41,72732 claims
GSKTrelegy Ellipta$192$34,90231 claims
AbbVieSynthroid$425$2,89268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →